• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳头瘤病毒L1蛋白疫苗(希瑞适和佳达修)在降低宫颈上皮内瘤变风险方面的疗效:一项荟萃分析。

Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis.

作者信息

Haghshenas Mohammad Reza, Mousavi Tahoora, Kheradmand Motahareh, Afshari Mahdi, Moosazadeh Mahmood

机构信息

Department of Microbiology, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Student Research Committee, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

出版信息

Int J Prev Med. 2017 Jun 1;8:44. doi: 10.4103/ijpvm.IJPVM_413_16. eCollection 2017.

DOI:10.4103/ijpvm.IJPVM_413_16
PMID:28656100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5474905/
Abstract

Human papillomavirus (HPV) can induce cervical intraepithelial neoplasia (CIN). Vaccination against HPV can play an important role in CIN prevention. This study aims to estimate the efficacy of L1 protein vaccines (Cervarix and Gardasil) in CIN 1, 2, 3 risk reduction using meta-analysis. Relevant articles were identified by two independent researchers searching international databanks. After application of inclusion/exclusion criteria and quality assessment, eligible articles were entered into the final meta-analysis. Inverse variance method and fixed effect model were used to combine the results of the primary studies. The heterogeneity between the results was assessed using Cochrane and indices. Of 11,530 evidence identified during the primary search, three papers were found eligible for meta-analysis, including 7213 participants in the intervention groups and 7170 healthy controls. The efficacy (95% confidence interval) of HPV 6, 11, 16, 18 monovalent and quadrivalent vaccines against CIN 1, CIN 2, and CIN 3 were estimated as of 95% (88-98), 97% (85-99), and 95% (78-99), respectively. This study showed that L1 protein vaccines Cervarix and Gardasil are highly protective vaccines playing an effective role in the prevention of HPV 6, 11, 16, 18 which are responsible for CIN 1, CIN 2, and CIN 3.

摘要

人乳头瘤病毒(HPV)可诱发宫颈上皮内瘤变(CIN)。接种HPV疫苗在预防CIN方面可发挥重要作用。本研究旨在通过荟萃分析评估L1蛋白疫苗(希瑞适和加德西)在降低CIN 1、2、3风险方面的疗效。两名独立研究人员通过检索国际数据库来识别相关文章。在应用纳入/排除标准并进行质量评估后,符合条件的文章被纳入最终的荟萃分析。采用逆方差法和固定效应模型来合并主要研究的结果。使用Cochrane和 指数评估结果之间的异质性。在初步检索中识别出的11530条证据中,发现有三篇论文符合荟萃分析的条件,干预组包括7213名参与者,健康对照组包括7170名。HPV 6、11、16、18单价和四价疫苗针对CIN 1、CIN 2和CIN 3的疗效(95%置信区间)分别估计为95%(88 - 98)、97%(85 - 99)和95%(78 - 99)。本研究表明,L1蛋白疫苗希瑞适和加德西是高度保护性疫苗,在预防导致CIN 1、CIN 2和CIN 3的HPV 6、11、16、18方面发挥着有效作用。

相似文献

1
Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis.人乳头瘤病毒L1蛋白疫苗(希瑞适和佳达修)在降低宫颈上皮内瘤变风险方面的疗效:一项荟萃分析。
Int J Prev Med. 2017 Jun 1;8:44. doi: 10.4103/ijpvm.IJPVM_413_16. eCollection 2017.
2
Current prophylactic HPV vaccines and gynecologic premalignancies.当前预防性 HPV 疫苗与妇科癌前病变。
Curr Opin Obstet Gynecol. 2009 Dec;21(6):457-64. doi: 10.1097/GCO.0b013e328332c910.
3
Human papillomavirus vaccines.人乳头瘤病毒疫苗
Ann Pharmacother. 2006 Jul-Aug;40(7-8):1344-52. doi: 10.1345/aph.1G723. Epub 2006 Jul 18.
4
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.两种人乳头瘤病毒疫苗的交叉保护效力:系统评价和荟萃分析。
Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22.
5
Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.基于L1病毒样颗粒的人乳头瘤病毒疫苗对有既往HPV暴露证据的女性肛门生殖器癌前病变疗效的系统评价和荟萃分析
PLoS One. 2014 Mar 3;9(3):e90348. doi: 10.1371/journal.pone.0090348. eCollection 2014.
6
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.AS04 佐剂人乳头瘤病毒 16/18 型宫颈癌疫苗(佳达修)的临床更新。
Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18.
7
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.18至45岁健康女性中,希瑞适和加德西人乳头瘤病毒(HPV)宫颈癌疫苗的免疫原性和安全性比较。
Hum Vaccin. 2009 Oct;5(10):705-19. doi: 10.4161/hv.5.10.9518. Epub 2009 Oct 14.
8
Evaluation of the Therapeutic Effect of Quadrivalent Human Papillomavirus (HPV) Vaccination on Cervical Intraepithelial Neoplasia Lesions.四价人乳头瘤病毒(HPV)疫苗接种对宫颈上皮内瘤变病变的治疗效果评估。
Indian J Surg Oncol. 2023 Jun;14(2):504-509. doi: 10.1007/s13193-022-01657-w. Epub 2022 Oct 1.
9
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.预防性人乳头瘤病毒L1病毒样颗粒疫苗临床试验结果的更新
Vaccine. 2008 Aug 19;26 Suppl 10(Suppl 10):K53-61. doi: 10.1016/j.vaccine.2008.06.002.
10
Human papillomavirus vaccination in adolescence.青少年人乳头瘤病毒疫苗接种。
Perspect Public Health. 2013 Nov;133(6):320-4. doi: 10.1177/1757913913499091. Epub 2013 Sep 4.

引用本文的文献

1
Current status and future directions for the development of human papillomavirus vaccines.人乳头瘤病毒疫苗的发展现状和未来方向。
Front Immunol. 2024 Jun 25;15:1362770. doi: 10.3389/fimmu.2024.1362770. eCollection 2024.
2
Vaccine: Antigens and Mucosal Adjuvants.疫苗:抗原与黏膜佐剂
Vaccines (Basel). 2024 Jun 4;12(6):619. doi: 10.3390/vaccines12060619.
3
Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.基于多表位L2的人乳头瘤病毒抗原中表位间间隔变异影响免疫原性。

本文引用的文献

1
The Prevalence of Cervical Human Papillomavirus Infection and the Most At-risk Genotypes Among Iranian Healthy Women: A Systematic Review and Meta-analysis.伊朗健康女性中宫颈人乳头瘤病毒感染的患病率及最高危基因型:一项系统评价和荟萃分析
Int J Prev Med. 2016 May 4;7:70. doi: 10.4103/2008-7802.181756. eCollection 2016.
2
Human papillomavirus and breast cancer in Iran: a meta- analysis.伊朗的人乳头瘤病毒与乳腺癌:一项荟萃分析。
Iran J Basic Med Sci. 2016 Mar;19(3):231-7.
3
The quality of reports of randomized clinical trials on traditional Chinese medicine treatments: a systematic review of articles indexed in the China National Knowledge Infrastructure database from 2005 to 2012.
NPJ Vaccines. 2024 Feb 24;9(1):44. doi: 10.1038/s41541-024-00832-0.
4
Vaccine Strategies to Elicit Mucosal Immunity.诱导黏膜免疫的疫苗策略。
Vaccines (Basel). 2024 Feb 13;12(2):191. doi: 10.3390/vaccines12020191.
5
Low presence of papillomavirus and its lack of correlation with clinicopathological factors in breast cancer: a case control study.人乳头瘤病毒在乳腺癌中的低感染率及其与临床病理因素的不相关性:一项病例对照研究
Iran J Microbiol. 2023 Aug;15(4):585-593. doi: 10.18502/ijm.v15i4.13513.
6
Human papillomavirus (HPV) infection and vaccination: A cross-sectional study of college students' knowledge, awareness, and attitudes in Villanova, PA.人乳头瘤病毒(HPV)感染与疫苗接种:宾夕法尼亚州维拉诺瓦市大学生知识、认知及态度的横断面研究
Vaccine X. 2022 Jan 17;10:100141. doi: 10.1016/j.jvacx.2022.100141. eCollection 2022 Apr.
7
Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.混合噬菌体 MS2-L2 VLP 诱导针对 HPV 假病毒 51 的持久保护性抗体。
Viruses. 2021 Jun 10;13(6):1113. doi: 10.3390/v13061113.
8
Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.病毒样颗粒 (VLPs) 与树突状细胞 (DCs) 模式识别受体 (PRRs) 的相互作用:更好地工程化 VLPs。
Front Immunol. 2020 Jun 9;11:1100. doi: 10.3389/fimmu.2020.01100. eCollection 2020.
9
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?基于病毒样颗粒的抗人乳头瘤病毒疫苗:我们如今进展如何?
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
10
Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment.使用第一代纳米贴片(Nanopatch™)皮内注射无佐剂人乳头瘤病毒疫苗在恒河猴中的免疫反应和反应原性:一项探索性临床前可行性评估
Vaccine X. 2019 Jun 20;2:100030. doi: 10.1016/j.jvacx.2019.100030. eCollection 2019 Aug 9.
中药治疗随机临床试验报告质量:2005 年至 2012 年中国知识基础设施数据库收录文章的系统评价。
BMC Complement Altern Med. 2014 Sep 26;14:362. doi: 10.1186/1472-6882-14-362.
4
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.苏格兰与二价人乳头瘤病毒疫苗高接种率相关的低级别和高级别宫颈异常减少。
Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 10.1038/bjc.2014.479. Epub 2014 Sep 2.
5
Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study.宫颈癌患者高危型人乳头瘤病毒的流行状况及型别分布:一项基于人群的研究。
Infect Agent Cancer. 2013 Jun 6;8(1):20. doi: 10.1186/1750-9378-8-20.
6
Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions.实时PCR鉴定的高危型人乳头瘤病毒(HPV)相关性在宫颈瘤前病变中的作用
Eur J Gynaecol Oncol. 2012;33(5):467-71.
7
Advances in human papilloma virus vaccines: a patent review.人乳头瘤病毒疫苗的研究进展:专利述评
Expert Opin Ther Pat. 2011 Mar;21(3):295-309. doi: 10.1517/13543776.2011.551114. Epub 2011 Jan 21.
8
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.人乳头瘤病毒基因型在宫颈癌中的分布:一项回顾性、全球性的横断面研究。
Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.
9
Currently approved prophylactic HPV vaccines.目前已批准的预防性 HPV 疫苗。
Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123.
10
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.四价人乳头瘤病毒(6、11、16、18型)病毒样颗粒疫苗对16至24岁欧洲女性的影响。
J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1147-55. doi: 10.1111/j.1468-3083.2009.03266.x. Epub 2009 Apr 23.